エピソード

  • RXRX Today - Aug 13: Slight Uptick in Value

    RXRX Today - Aug 13: Slight Uptick in Value
    2026/08/13
    Hey there! It’s Joey, your friendly neighborhood investor, here to break down today’s stock action. We’re talking about Recursion, ticker RXRX. It was a green day for them, up just a smidge—about 0.6 percent. Not a huge leap, but hey, green is good, right?

    So, what went down? The stock kinda cruised along today, with some decent volume but not really popping off. It opened around 3.27 and climbed a bit to finish at 3.31. Nothing too crazy, but it’s nice to see it in the green rather than red, you know?

    Now, why did it move like this? Well, there’s some chatter about Recursion hitting an inflection point, according to their CEO. That’s a fancy way of saying they might be turning a corner on their growth or pipeline. They had some good news about their Q4 performance, which got people a bit excited in pre-market trading. But then, it kinda settled down once the day rolled on. Plus, there’s some interesting stuff happening with options trading—people are buying a lot of put options, which usually means they’re hedging against a potential drop. So, yeah, there’s a mix of optimism and caution in the air.

    And just a heads-up, Recursion did file a notice about a proposed sale of securities. That’s just a formality, but it can sometimes make investors a little twitchy. It’s like, “What’s the plan here?”

    To wrap it up, RXRX had a slightly positive day with some potential good vibes about their future, but there’s also a bit of unease with those put options floating around. Just keep your eyes peeled, folks. Remember, I’m just here sharing what I see, not giving any financial advice. Catch you later!
    続きを読む 一部表示
    2 分
  • RXRX Today - Aug 12: Short Interest Rises

    RXRX Today - Aug 12: Short Interest Rises
    2026/08/12
    Hey there! It’s Joey here, your go-to guy for stock chat. I’ve been in the investing game for a while now, and today we're talking about Recursion, ticker RXRX. Spoiler alert: it was a red day for them, down about 1.6%.

    So, what happened? Recursion got smoked today. The stock took a hit, and it seems like traders were feeling pretty nervous. There was a lot of chatter about short interest rising to over 35%. That’s a big deal! When more people are betting against a stock, it can really shake things up. Plus, I saw some reports about folks buying up put options, which kinda signals that people were expecting more downside. Not a great vibe for the bulls.

    Now, why did this happen? Well, it looks like there’s some concern about Recursion's growth. They’ve been pushing hard on their AI drug discovery partnerships, but even with that, they’re facing a cash burn and slow growth. That can freak investors out. Plus, there was some bearish sentiment floating around in the air, especially after a recent article pointed out that even with the Genentech news, there’s still a lot of skepticism about Recursion's future. Yeah, that one stung.

    On the horizon, there’s a notice of proposed sale of securities under Rule 144. That could mean they’re looking to raise some cash, which is worth keeping an eye on. It’s like, more dilution might be coming down the line, and nobody loves that.

    So, to wrap it up, Recursion had a tough day with a lot of noise about short selling and concerns over their growth strategy. It’s a wild ride in the biotech space, and RXRX is right in the middle of it. Just remember, this is all for fun and info—no financial advice here. Catch you later!
    続きを読む 一部表示
    2 分
  • RXRX Today - Aug 11: Analysts Trim Revenue Forecasts

    RXRX Today - Aug 11: Analysts Trim Revenue Forecasts
    2026/08/11
    Hey, what’s up? It’s Joey here, your friendly neighborhood investor, breaking down the day for you. Today, we’re chatting about Recursion, RXRX. It was a bit of a mixed bag, but overall, it ended up in the green, gaining about 1.4%. Not a huge move, but hey, at least it didn’t get smoked, right?

    So, here’s the scoop. RXRX had a pretty chill trading day with decent volume, but there’s a lot more going on behind the scenes. The stock’s been buzzing with some mixed news lately. On one hand, there’s been chatter about their partnerships in AI drug discovery, which sounds cool and all, but the reality is that they’re facing some serious cash burn and slow growth. Not exactly the vibes you want when you’re trying to boost a stock’s value.

    Now, let’s talk about why the stock moved today. Analysts just trimmed their revenue forecasts for Recursion by a whopping 19%. Ouch! That definitely got some folks worried. When analysts start cutting estimates like that, it usually sends investors scrambling for the exit. Plus, there’s chatter about a proposed sale of securities, which can make people a bit uneasy. It’s like, “What do they know that we don’t?”

    And speaking of uncertainty, Recursion’s earnings call just dropped, and while they had some news, it didn’t exactly light the world on fire. Investors are still feeling the heat from all these mixed signals. So yeah, people are definitely on edge with RXRX right now.

    One thing to keep an eye on is how these partnerships in AI drug discovery pan out. They’ve got potential, but if Recursion can’t get a handle on that cash burn, it might be a rough ride.

    Alright, that’s a wrap for today! Just a heads up, this is all for your info and entertainment—no financial advice here. Catch you later!
    続きを読む 一部表示
    2 分
  • RXRX Today - Aug 10: Analysts Trim Revenue Forecasts

    RXRX Today - Aug 10: Analysts Trim Revenue Forecasts
    2026/08/10
    Hey there! It’s Joey, your friendly investor, and I'm here to break down what went down with Recursion, or RXRX, today. Spoiler alert: it was a red day, down about 2.5%.

    So, what happened? RXRX started off with some mixed vibes after their Q2 results came out. They reported a narrower net loss, which usually gets people a little excited, right? But then analysts came in and dropped their revenue forecasts by a whopping 19%. Yeah, that one stung. People were quick to hit the sell button, and it showed in the stock price.

    Now, let’s unpack why this all went down. The earnings call highlighted that while they’re making progress, folks are worried about those revenue cuts. Investors want to see growth, and when the numbers aren’t looking promising, it’s a hard pill to swallow. Plus, with AbCellera’s shares surging, some investors might be looking for greener pastures elsewhere. It’s tough out there!

    Looking ahead, one thing to keep in mind is that Recursion is still in the game. They've got more trials and developments lined up, so while today's news was a bummer, there’s still potential on the horizon.

    Alright, that’s the scoop on RXRX today! Remember, this is just me sharing info, not financial advice. Keep it chill and happy investing!
    続きを読む 一部表示
    1 分
  • RXRX Today - Aug 09: Mixed Q2 Results Reaction

    RXRX Today - Aug 09: Mixed Q2 Results Reaction
    2026/08/09
    Hey, what's up? It’s Joey here, your friendly longtime investor. Today, we’re talking about Recursion Pharmaceuticals, or RXRX. It had a red day, down about 1.26%.

    So, here’s the scoop. RXRX opened a bit shaky and just kinda trailed off. It was hanging around the same spot for most of the day, but it did get a little boost earlier when news dropped about their Q2 results. They reported a narrower net loss, which is kinda good, but overall, the revenue pressure seems to be weighing on folks’ minds.

    Now, why the mixed reactions? Well, people were stoked about the narrower loss – you know, less bad news is still good news – but then they looked closer and saw revenue wasn’t exactly crushing it. So, it’s like a double-edged sword. Some investors hit the sell button fast, probably worried about future earnings. Plus, there was some insider selling going on. Their director Blake Borgeson sold off nearly $100,000 in stock. That usually raises some eyebrows, right?

    And just to keep it real, there’s always some uncertainty with stocks like this. Nobody really knows if that insider selling is a red flag or just a regular thing.

    One thing to keep an eye on is the upcoming news about AbCellera. Their shares are surging ahead of some major trial results on Monday. That might shake up the biotech space a bit, and who knows, it could impact RXRX too since they’re all in that same industry.

    Alright, that’s the lowdown for today. Just remember, I’m here to keep you informed and entertained, not to give financial advice. Stay savvy, my friend!
    続きを読む 一部表示
    2 分
  • RXRX Today - Aug 08: Revenue Pressure Hits Hard

    RXRX Today - Aug 08: Revenue Pressure Hits Hard
    2026/08/08
    Hey, what’s up? It’s Joey here, your friendly neighborhood investor, and I’m breaking down what happened with Recursion, or RXRX, today. It was a red day, folks, down about 1.3%.

    So, what went down? The stock was kinda flat for most of the day but ended slightly lower. Nothing too dramatic, but definitely not the vibe you want to see. Volume was pretty average, so it wasn’t like a crazy sell-off or anything.

    Now, let’s chat about why this happened. Recursion just reported some Q2 revenue pressure, which is never a good look. Investors are worried that the gap between what the company is worth and what it's actually bringing in is getting way too big. You know how it is—when a company’s not hitting those revenue targets, people start hitting the sell button fast. Plus, there was news that a director, Blake Borgeson, sold off around $97,500 worth of stock. That kind of insider selling can make folks nervous, like “What do they know that I don’t?”

    And it doesn’t stop there. There’s chatter in the market about AI drug discovery stocks facing a lot of threats right now. Yeah, that one stung a bit for Recursion, since they’re in that space. Investors are probably feeling the pressure, and it’s got them thinking twice about where to put their money.

    One thing worth keeping an eye on? The ongoing conversation around the valuation gap. It's getting a lot of buzz, and it could impact how the stock moves in the near future.

    So, to wrap it up, Recursion had a tough day, mostly due to revenue concerns and insider selling. Always a bummer when that happens. Just remember, this is all for your info and entertainment, not financial advice. Catch you later!
    続きを読む 一部表示
    2 分
  • RXRX Today - Aug 07: Insider Selling Sparks Caution

    RXRX Today - Aug 07: Insider Selling Sparks Caution
    2026/08/07
    Hey there! It’s Joey here, your friendly neighborhood investor, breaking down the day for Recursion, ticker RXRX. Today was a bit of a mixed bag, but it ended up in the green, moving up about 1.3%. Not too shabby!

    So, what happened? Well, RXRX had a decent day, gaining a little ground. But here’s the kicker—there’s been some buzz about insider selling, which always gets people a bit jittery. Blake Borgeson, a director at Recursion, sold around $97,500 worth of shares. That’s a big chunk, and it’s got folks raising their eyebrows. Plus, there’s been chatter about other insiders cashing out, totaling nearly $790k. Yeah, that one stung a bit for investors. When insiders start selling, it can feel like they know something we don’t, you know?

    Now, why is this happening? Well, the market’s been a bit shaky on Recursion's returns, and some analysts think the stock’s trading above its fair value. So, when insiders sell, it can signal a bit of caution, and people start hitting that sell button fast. It’s all about confidence, right? If the folks running the show are selling, it makes you wonder what they see that we might not.

    On a brighter note, there was some positive news too! Recursion and Roche are pushing forward with an AI-driven target for brain disease. That’s some exciting stuff! It shows they’re not just sitting on their hands, and there’s potential for innovation here. But, yeah, that insider selling is definitely casting a shadow over the excitement.

    To wrap it up, RXRX had a little win today, but the insider selling is making people cautious. Always something interesting happening in the stock world, huh? Just remember, this is all for fun and info—no financial advice here! Catch you later!
    続きを読む 一部表示
    2 分
  • RXRX Today - Aug 06: Cash Burn Concerns

    RXRX Today - Aug 06: Cash Burn Concerns
    2026/08/06
    Hey there! I’m Joey, your friendly longtime investor, and I’m breaking down what went down with Recursion, or RXRX, today. Spoiler alert: it was a red day. The stock dipped about 0.36%.

    So, here’s the scoop. RXRX got smoked today. It seems like cash burn is the big worry for folks right now. Investors are feeling the heat after the company reported a Q2 loss and missed revenue estimates. Not a great look, right? People were already on edge after the results update from August 5, and it seems like this just added fuel to the fire.

    Now, let’s chat about why this happened. The articles are saying Recursion's been struggling with returns and is trading above what some think is fair value. Basically, it’s like when you’re trying to sell a used game for way too much, and no one’s biting. Plus, the whole AI drug development angle hasn’t been enough to convince everyone that it’s worth the price tag. Investors are questioning if the hype around AI in drug discovery is really living up to the expectations.

    Oh, and here’s something worth knowing: Roche and Recursion are still pushing forward with their AI-targeted brain disease project. So, there’s some action happening in the lab, but it seems like the market’s not super jazzed about the immediate financials.

    To wrap it up, RXRX is facing some tough questions from investors, and it’s clear that cash burn is a hot topic. Remember, I’m just here to share what’s happening, not to give any financial advice. Keep it chill, and see you next time!
    続きを読む 一部表示
    1 分